Gregorio Guillen

Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020.

Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020.

Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020.

Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020.